134 chapter 2 Table 14. Baseline characteristics of included studies investigating RET/PTC rearrangements reference country study design ntot ni included indeterminate cytology Sapio 2007 (2) Italy n.s. 132 21 indeterminate Cantara 2010 Italy PS 235 41 indeterminate Moses 2010 USA PS 455 110 follicular or Hürthle cell neoplasm Guerra 2011 Italy PS 185 24 Thy3 Nikiforov 2011 USA PS 1,056 461 Bethesda III or IV Mancini 2012 Italy n.s. 260 48 Thy3 Ohori 2013 USA RS 483 424 Bethesda IV, excluding SHCN/HCN Beaudenon-Huibregtse 2014 USA PS 806 80 Bethesda III or IV Eszlinger 2014 (1) Denmark RS 310 164 indeterminate Eszlinger 2014 (2) Germany PS 154 125 follicular neoplasm or microfollicular proliferation Liu 2014 China PS 314 52 Bethesda III or IV Nikiforov 2014 USA PS+RS 143 143 Bethesda IV Eszlinger 2015 Italy RS 347 163 Thy3 Giovanella 2015 Switzerland PS 61 61 Bethesda IV Nikiforov 2015 USA PS 465 462 Bethesda III Rossi 2015 Italy PS 940 118 Bethesda III or IV Valderrabano 2016 USA RS 116 105 Bethesda III or IV TOTAL 6,462 2,602 FFPE: formalin-fixed paraffin embedded. FMCA: fluorescence melting curve analysis. f/u: follow-up. HRM: High resolution melting. ni: total number of indeterminate thyroid nodules included in our analysis. n.o.s.: not otherwise specified. n.s.: not specified. ntot: total number of thyroid nodules in study. PS: prospective. PCR: polymerase chain reaction. qPCR: quantitative PCR. RS: retrospective. RT-PCR: reverse transcription PCR. SHCN/ HCN: cytology (suspicious for a) Hürthle cell neoplasm. TN: thyroid nodule.
RkJQdWJsaXNoZXIy MTk4NDMw